Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Myeloproliferative Disorders 2 Leukemia, Myelomonocytic, Chronic 2 Myelodysplastic Syndromes 1 Lymphoma, Mantle-Cell 1 Leukemia, Myeloid, Acute 1 Esophageal Neoplasms 1

Interventions

Cisplatin 109 Radiotherapy 100 Fluorouracil 90 Paclitaxel 75 Oxaliplatin 63 Docetaxel 56 Carboplatin 55 Irinotecan 41 Esophagectomy 41 Leucovorin 40 Capecitabine 39 Surgical Procedures, Operative 36 Radiation 36 Drug Therapy 31 Neoadjuvant Therapy 25 Chemoradiotherapy 18 Cetuximab 18 S 1 (combination) 17 pembrolizumab 16 camrelizumab 16 Nivolumab 15 Magnetic Resonance Spectroscopy 15 Bevacizumab 15 Blood Specimen Collection 14 Surveys and Questionnaires 12 Radiotherapy, Intensity-Modulated 12 Immunotherapy 11 Epirubicin 11 Biopsy 11 Trastuzumab 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Esophageal Neoplasms × eprenetapopt × Clear all

NCT02999893 2021-12-13

APROC

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Terminated

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡